Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
Public ClinicalTrials.gov record NCT01483625. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms. It also represents an opportunity to identify COPD patients earlier in their disease state and start maintenance therapy, if appropriate.
Study identification
- NCT ID
- NCT01483625
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2011 (Type not available)
- Primary completion
- Dec 2012 (Actual)
- Completion
- Dec 2012 (Actual)
- Last update posted
- Jun 9, 2014
2011 – 2012
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.479.01017 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 205.479.01036 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 205.479.01024 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.479.01043 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 205.479.01040 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 205.479.01022 Boehringer Ingelheim Investigational Site | Chelsea | Michigan | — | — |
| 205.479.01041 Boehringer Ingelheim Investigational Site | Picayune | Mississippi | — | — |
| 205.479.01037 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 205.479.01005 Boehringer Ingelheim Investigational Site | Tabor City | North Carolina | — | — |
| 205.479.01008 Boehringer Ingelheim Investigational Site | Wilmington | North Carolina | — | — |
| 205.479.01003 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.479.01002 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 205.479.01044 Boehringer Ingelheim Investigational Site | Tipton | Pennsylvania | — | — |
| 205.479.01006 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.479.01001 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 205.479.01007 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 205.479.01026 Boehringer Ingelheim Investigational Site | Fort Mill | South Carolina | — | — |
| 205.479.01031 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 205.479.01012 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 205.479.01048 Boehringer Ingelheim Investigational Site | Hodges | South Carolina | — | — |
| 205.479.01004 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 205.479.01019 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 205.479.01039 Boehringer Ingelheim Investigational Site | Rapid City | South Dakota | — | — |
| 205.479.01033 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 205.479.01028 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 205.479.01038 Boehringer Ingelheim Investigational Site | Ettrick | Virginia | — | — |
| 205.479.01047 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01483625, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01483625 live on ClinicalTrials.gov.